Ovid Therapeutics Inc. (24)

Browse by Contract Category

Contracts

(Filed With SEC on May 10, 2022)
Non-Employee Director Compensation Policy, effective May 5, 2022 (Filed With SEC on May 10, 2022)
License Agreement, dated as of December 30, 2021, by and between the Ovid Therapeutics Inc. and AstraZeneca AB (Filed With SEC on January 3, 2022)
Royalty, License and Termination Agreement, by and between the Company and Takeda Pharmaceutical Company Limited, dated March 2, 2021 (Filed With SEC on May 13, 2021)
Underwriting Agreement related to the Offering, dated August 25, 2020, among Ovid Therapeutics Inc. and Cowen and Company, LLC and William Blair & Company, L.L.C (Filed With SEC on August 26, 2020)
Non-Employee Director Compensation Policy, effective May 6, 2021 (Filed With SEC on November 10, 2021)
Amended and Restated Executive Employment Agreement between the Company and Jeffrey Rona, effective June 2, 2021 (Filed With SEC on August 16, 2021)
Collaboration and License Agreement, by and between the Company and Angelini Pharma Rare Diseases AG, dated July 9, 2020 (Filed With SEC on March 15, 2021)
Amended and Restated Executive Employment Agreement between the Company and Thomas Perone, effective January 1, 2020 (Filed With SEC on March 15, 2021)
Executive Employment Agreement between the Company and Jason Tardio, effective October 21, 2019 (Filed With SEC on March 15, 2021)
Executive Employment Agreement between the Company and Jeff Rona, effective September 30, 2020 (Filed With SEC on March 15, 2021)
Collaboration and License Agreement, by and between the Company and Angelini Pharma Rare Diseases AG, dated July 9, 2020 (Filed With SEC on November 13, 2020)
Third Amended and Restated Executive Employment Agreement between the Company and Tim Daly, effective December 18, 2019 (Filed With SEC on March 11, 2020)
Second Amended and Restated Executive Employment Agreement between the Company and Amit Rakhit, effective November 1, 2019 (Filed With SEC on March 11, 2020)
Non-Employee Director Compensation Plan (Filed With SEC on March 11, 2020)
Description of the Securities of Ovid Therapeutics Inc (Filed With SEC on March 11, 2020)
Underwriting Agreement related to the Preferred Offering, dated October 4, 2019, among Ovid Therapeutics Inc. and Cowen and Company, LLC and William Blair & Company, L.L.C (Filed With SEC on October 8, 2019)
Underwriting Agreement related to the Common Offering, dated October 4, 2019, among Ovid Therapeutics Inc. and Cowen and Company, LLC and William Blair & Company, L.L.C (Filed With SEC on October 8, 2019)
Exchange Agreement among Ovid Therapeutics Inc. and Biotechnology Value Fund, L.P., Biotechnology Value Fund II, L.P. and Biotechnology Value Trading Fund OS, L.P., dated... (Filed With SEC on September 19, 2019)
Lundbeck Amendment (Filed With SEC on June 17, 2019)
Separation and Consulting Agreement, by and between the Company and Matthew During, dated as of March 24, 2019 (Filed With SEC on May 7, 2019)
Underwriting Agreement related to the Preferred Offering, dated February 20, 2019, among Ovid Therapeutics Inc. and Cowen and Company, LLC and William Blair & Company, L.L.C (Filed With SEC on February 21, 2019)
Form of Series A Preferred Stock Certificate (Filed With SEC on February 21, 2019)
Underwriting Agreement related to the Common Offering, dated February 20, 2019, among Ovid Therapeutics Inc. and Cowen and Company, LLC and William Blair & Company, L.L.C (Filed With SEC on February 21, 2019)